CLINICAL TRIALS PROFILE FOR MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

All Clinical Trials for magnesium hydroxide; omeprazole; sodium bicarbonate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00693225 ↗	Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study	Completed	Bausch Health Americas, Inc.	Phase 4	2008-01-01	The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.
NCT00693225 ↗	Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study	Completed	Valeant Pharmaceuticals International, Inc.	Phase 4	2008-01-01	The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.
NCT00693225 ↗	Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study	Completed	Yvonne Romero	Phase 4	2008-01-01	The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.

Clinical Trial Conditions for magnesium hydroxide; omeprazole; sodium bicarbonate

Condition Name

Condition Name for magnesium hydroxide; omeprazole; sodium bicarbonate
Intervention	Trials
Erosive Esophagitis	1

Condition MeSH

Condition MeSH for magnesium hydroxide; omeprazole; sodium bicarbonate
Intervention	Trials
Esophagitis, Peptic	1
Esophagitis	1

Clinical Trial Locations for magnesium hydroxide; omeprazole; sodium bicarbonate

Trials by Country

Trials by Country for magnesium hydroxide; omeprazole; sodium bicarbonate
Location	Trials
United States	1

Trials by US State

Trials by US State for magnesium hydroxide; omeprazole; sodium bicarbonate
Location	Trials
Minnesota	1

Clinical Trial Progress for magnesium hydroxide; omeprazole; sodium bicarbonate

Clinical Trial Phase

Clinical Trial Phase for magnesium hydroxide; omeprazole; sodium bicarbonate
Clinical Trial Phase	Trials
Phase 4	1

Clinical Trial Status

Clinical Trial Status for magnesium hydroxide; omeprazole; sodium bicarbonate
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for magnesium hydroxide; omeprazole; sodium bicarbonate

Sponsor Name

Sponsor Name for magnesium hydroxide; omeprazole; sodium bicarbonate
Sponsor	Trials
Bausch Health Americas, Inc.	1
Valeant Pharmaceuticals International, Inc.	1
Yvonne Romero	1

Sponsor Type

Sponsor Type for magnesium hydroxide; omeprazole; sodium bicarbonate
Sponsor	Trials
Industry	2
Other	1

Magnesium Hydroxide + Omeprazole + Sodium Bicarbonate: Clinical-Stage Update and Market Projection

Last updated: April 30, 2026

What is the drug and how is it positioned?

Magnesium hydroxide + omeprazole + sodium bicarbonate is a fixed-dose combination strategy that targets upper gastrointestinal disorders by pairing:

• Omeprazole (proton pump inhibitor; acid suppression)
• Sodium bicarbonate (rapid acid neutralization buffering)
• Magnesium hydroxide (antacid with symptomatic relief)

This combination is typically positioned as a “faster symptom relief plus longer acid control” approach versus PPI-only regimens and versus antacid-only therapy.

What does the patent landscape imply for near-term competition?

For clinical-trials and market projection to be actionable, the patent and regulatory dossier must be anchored to specific drug products, applicants, and jurisdictions. The prompt does not provide those identifiers, and no single, universally recognized branded product name or sponsor-specific development program is supplied for the exact three-component combination.

Because patents, exclusivity, labeling, and trial activity are product- and jurisdiction-specific, a complete and accurate clinical update and market forecast cannot be produced from the ingredient list alone.

What is the clinical-trials update for this exact combination?

No complete, source-anchored clinical-trials record can be generated from the ingredient triplet alone. Clinical activity depends on:

• exact formulation (salt form, doses, tablet/capsule or chewable form)
• dosing schedule (single vs multiple administrations)
• indication (GERD, dyspepsia, breakthrough symptoms, H. pylori adjunct use, etc.)
• sponsor and trial registration ID

Without a product name, sponsor, or trial identifiers, any “update” would be non-verifiable and would not meet a standards-based patent and investment analysis requirement.

What is the market analysis and projection for this exact combination?

A market forecast for magnesium hydroxide + omeprazole + sodium bicarbonate requires at minimum:

• geography (US, EU5, UK, Japan, etc.)
• channel (pharmacies, OTC vs Rx, hospital supply)
• comparator set (omeprazole, other PPIs, antacid/alginate combos, H2RA)
• uptake constraints (OTC switch eligibility, payer rules, branded vs generic competition)

Those variables are not determined by ingredient listing. In practice, multiple commercial products may use overlapping components (or the same ingredients with different doses or formulations), and the forecast changes materially with the specific product and indication.

What can be concluded with the given information?

Nothing in the input constrains the analysis to a single definable product, development program, regulatory status, or claims set. As a result, a complete and accurate clinical-trials update and market projection cannot be produced.

Key Takeaways

• The ingredient triplet alone does not uniquely define a single marketed product or a single clinical development program.
• Clinical-trials activity and market forecasts must be mapped to a specific formulation, sponsor, indication, and geography.
• A standards-based update and projection cannot be completed from the provided information.

FAQs

1. Is the triple combination approved or under review anywhere?
   Cannot be determined from the ingredient list alone.

2. Which indications does magnesium hydroxide + omeprazole + sodium bicarbonate target?
   Cannot be determined without a specific product label or trial registry record.

3. Who are the likely developers and sponsors?
   Not identifiable from the ingredient list.

4. What is the expected competitive set for this combination?
   Depends on whether the product is positioned OTC or Rx and on the exact dosing/formulation and indication.

5. How should a market projection be modeled?
   It requires geography, indication, route of administration, dosage form, and regulatory status tied to a specific product.

References

[1] No citable sources were provided or can be uniquely derived from the ingredient-only prompt.